AbbVie Inc. (ABBV) company profile
Close on Nov 13, 2026Market cap $521.35BP/E 83.3Yield 2.25%
About AbbVie
Pharmaceutical Preparations, SIC 2834
AbbVie is a biopharmaceutical company that discovers, develops, manufactures, and sells medicines and therapies. The company operates through a single global business segment covering therapeutic areas such as immunology, oncology, neuroscience, aesthetics, and eye care. Its key products include immunology medications such as Skyrizi, Rinvoq, and Humira; neuroscience therapies like Vraylar and Botox Therapeutic; oncology treatments including Imbruvica and Venclexta; and aesthetic offerings such as Botox Cosmetic and Juvederm fillers. AbbVie markets its products to physicians, healthcare providers, managed care organizations, hospitals, government agencies, and consumers. Its customers also include wholesale distributors, independent retailers, and specialty pharmacies.
The company distributes its products worldwide, maintaining company-owned distribution facilities and public warehouses. Its medicines are commercially available across North America, the European Union, Japan, and additional markets in South America, the Middle East, and Asia. In the United States, distribution relies primarily on independent wholesale distributors. The provided text notes that the company was incorporated in Delaware, but does not state a headquarters location.
Summary of the business section of AbbVie's latest annual report, written by StockData.
Company profile
Company
- Legal name
- AbbVie Inc.
- Founded
- 2012
- Headquarters
- North Chicago, IL
- Address
- 1 North Waukegan Road 60064
- Phone
- (847) 932-7900
- Website
- www.abbvie.com
- Employees
- 57,000, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst& Young LLP, Chicago, Illinois
Stock & identifiers
- Ticker
- ABBV
- Exchange
- NYSE
- IPO date
- Jan 2, 2013
- Shares outstanding
- 1.77B, Jul 27, 2026
- Public float
- $325.06B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1551152
- CUSIP
- 00287Y109
- ISIN
- US00287Y1091
- FIGI
- BBG0025Y4RY4
- Share class FIGI
- BBG0025Y4RZ3
- LEI
- FR5LCKFTG8054YNNRU85
- EIN
- 32-0375147
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Robert A. Michael | CHAIRMAN OF THE BOARD AND CEO, Director | 178,737 |
| Jeffrey Ryan Stewart | EVP, CHIEF COMMERCIAL OFFICER | 81,059 |
| Nicholas Donoghoe | EVP, CHIEF BUS/STRAT OFFICER | 74,430 |
| David Ryan Purdue | SVP, Controller | 9,011 |
| Demetris D. Crum | EVP, CHIEF HR OFFICER | 7,914 |
| Roopal Thakkar | EVP, R&D and CSO | 55,374 |
| Azita Saleki-Gerhardt | EVP, CHIEF OPERATIONS OFFICER | 204,373 |
| Perry C. Siatis | EVP, GC AND SECRETARY | 17,510 |
| Scott T. Reents | EVP, CHIEF FINANCIAL OFFICER | 38,777 |
| Inc. AbbVie | EVP, Chief HR Officer | 7,048 |
| Timothy J. Richmond | EVP, CHIEF HR OFFICER | 6,130 |
| Kevin K. Buckbee | SVP, CONTROLLER | 7,797 |
| John Carethers | Director | – |
| Susan E. Quaggin | Director | 3,643 |
| Edward J. Rapp | Director | 56,352 |
| Frederick H. Waddell | Director | 30,076 |
| Jennifer L. Davis | Director | 3,643 |
| Thomas J. Falk | Director | 5,321 |
| Brett J. Hart | Director | 20,590 |
| Rebecca B. Roberts | Director | 14,846 |
| William H.L. Burnside | Director | 28,076 |
| Thomas C. Freyman | Director | 133,810 |
| Melody B. Meyer | Director | 17,616 |
| Roxanne S. Austin | Director | 39,576 |
| Robert J. Alpern | Director | 35,646 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $32.53M | $57.37M | $12.12M | $259 | $187 |
| FY2024 Gonzalez | $28.50M | $67.57M | $11.31M | $195 | $151 |
| FY2024 Michael | $18.49M | $33.32M | $11.31M | $195 | $151 |
| FY2023 | $25.66M | $34.67M | $12.32M | $164 | $143 |
| FY2022 | $26.29M | $67.40M | $9.13M | $164 | $133 |
| FY2021 | $23.91M | $66.39M | $11.04M | $132 | $123 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Robert A. Michael Chairman of the Board and Chief Executive Officer | $1.70M | $13.27M | $3.20M | $5.20M | $9.16M | $32.53M | +76% |
| Scott T. Reents Executive Vice President, Chief Financial Officer | $1.12M | $4.35M | $1.05M | $2.35M | $3.48M | $12.35M | +12% |
| Jeffrey R. Stewart Executive Vice President, Chief Commercial Officer | $1.32M | $5.39M | $1.30M | $2.95M | $4.48M | $15.44M | +10% |
| Azita Saleki-Gerhardt Executive Vice President, Chief Operations Officer | $1.05M | $3.98M | $959.75K | $2.20M | $2.60M | $10.79M | +9% |
| Roopal B. Thakkar Executive Vice President, Research & Development and Chief Scientific Officer | $1.15M | $3.98M | $959.75K | $2.35M | $1.48M | $9.91M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“AbbVie employed approximately 57,000 employees in over 70 countries as of December 31, 2025.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?